Previous close | 9.53 |
Open | 9.59 |
Bid | 0.00 x 2200 |
Ask | 0.00 x 1000 |
Day's range | 9.25 - 9.65 |
52-week range | 6.88 - 26.60 |
Volume | |
Avg. volume | 348,073 |
Market cap | 371.043M |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.54 |
Earnings date | 08 Mar 2023 - 13 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.10 |
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
BEDFORD, Mass., January 09, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today outlined its expected milestones and the following strategic priorities for 2023:
BEDFORD, Mass., January 04, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET (11:15 a.m. PT).